JMI LABS IS NOW PART OF LEARN MORE

Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents.

Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents. by Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS and Jones RN published in J. Glob. Antimicrob. Resist. 2017; 8: 28-32

Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/beta-lactam combinations.

Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/beta-lactam combinations. by McLeod SM, Patey SA, Huband MD and Nichols WW published in Int. J. Antimicrob. Agents. 2017; 49 (4): 437-442

Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses.

Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. by Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, Colombo AL, Calvo B, Cuomo CA, Desjardins CA, Berkow EL, Castanheira M, Magobo RE, Jabeen K, Asghar RJ, Meis JF, Jackson B, Chiller T and Litvintseva AP published in Clin. Infect. Dis. 2017; 64 (2): 134-140

Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations.

Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations. by Jones RN, Flamm RK, Castanheira M, Sader HS, Smart JI and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2017; 88 (2): 184-187

Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design.

Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design. by Huband MD, Ito A, Tsuji M, Sader HS, Fedler KA and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2017; 88 (2): 198-200

Effect of susceptibility testing conditions on the in vitro antibacterial activity of ETX0914.

Effect of susceptibility testing conditions on the in vitro antibacterial activity of ETX0914. by Giacobbe RA, Huband MD, deJonge BL and Bradford PA published in Diag. Microbio. Infect. Dis. 2017; 87 (2): 139-142

In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae.

In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae. by Farrell DJ, Sader HS, Rhomberg PR, Scangarella-Oman NE and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (3): e02047

Empyema thoracis caused by an optrA-positive and linezolid-intermediate Enterococcus faecalis strain.

Empyema thoracis caused by an optrA-positive and linezolid-intermediate Enterococcus faecalis strain. by Chien JY, Mendes RE, Deshpande LM and Hsueh PR published in J. Infect. 2017; 75 (2): 182-184

Low frequency of ceftazidime-avibactam resistance among Enterobacteriaceae isolates carrying blaKPC collected in U.S. hospitals from 2012 to 2015.

Low frequency of ceftazidime-avibactam resistance among Enterobacteriaceae isolates carrying blaKPC collected in U.S. hospitals from 2012 to 2015. by Castanheira M, Mendes RE and Sader HS published in Antimicrob. Agents Chemother. 2017; 61 (3): e02369

Pseudomonas aeruginosa bacteremic patients exhibit nonprotective antibody titers against therapeutic antibody targets PcrV and Psl exopolysaccharide.

Pseudomonas aeruginosa bacteremic patients exhibit nonprotective antibody titers against therapeutic antibody targets PcrV and Psl exopolysaccharide. by Thaden JT, Keller AE, Shire NJ, Camara MM, Otterson L, Huband M, Guenther CM, Zhao W, Warrener P, Stover CK, Fowler VG, Jr. and DiGiandomenico A published in J. Infect. Dis. 2016; 213 (4): 640-648

Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata.

Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata. by Sanchis M, Capilla J, Castanheira M, Martin-Vicente A, Sutton DA, Fothergill AW, Wiederhold NP and Guarro J published in Int. J. Antimicrob. Agents. 2016; 47 (4): 286-288

In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis.

In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis. by Sanchez EH, Mendes RE, Sader HS and Allison GM published in J. Antimicrob. Chemother. 2016; 71 (6): 1736-1738

Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012-2014).

Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012-2014). by Sader HS, Mendes RE, Jones RN and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2016; 86 (1): 76-79

Antimicrobial activities of ceftazidime-avibactam and comparator agents against Gram-negative organisms isolated from patients with urinary tract infections in U.S. Medical Centers, 2012 to 2014.

Antimicrobial activities of ceftazidime-avibactam and comparator agents against Gram-negative organisms isolated from patients with urinary tract infections in U.S. Medical Centers, 2012 to 2014. by Sader HS, Castanheira M, Flamm RK and Jones RN published in Antimicrob. Agents. Chemother. 2016; 60 (7): 4355-4360

Ceftazidime-avibactam activity against aerobic Gram negative organisms isolated from intra-abdominal infections in United States hospitals, 2012-2014.

Ceftazidime-avibactam activity against aerobic Gram negative organisms isolated from intra-abdominal infections in United States hospitals, 2012-2014. by Sader HS, Castanheira M, Flamm RK, Huband MD and Jones RN published in Surg. Infect. (Larchmt). 2016; 17 (4): 473-478

Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: Results from SENTRY Antimicrobial Surveillance Program (2011-2014).

Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: Results from SENTRY Antimicrobial Surveillance Program (2011-2014). by Sader HS, Castanheira M, Farrell DJ, Flamm RK, Mendes RE and Jones RN published in Int. J. Antimicrob. Agents. 2016; 48 (2): 144-150

Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.

Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates. by Pfaller MA, Messer SA, Rhomberg PR, Jones RN and Castanheira M published in J. Antimicrob. Chemother. 2016; 71 (10): 2868-2873

Activities of tedizolid and linezolid determined by the reference broth microdilution method against 3,032 Gram-positive bacterial isolates collected in Asia-Pacific, Eastern Europe, and Latin American countries in 2014.

Activities of tedizolid and linezolid determined by the reference broth microdilution method against 3,032 Gram-positive bacterial isolates collected in Asia-Pacific, Eastern Europe, and Latin American countries in 2014. by Pfaller MA, Flamm RK, Jones RN, Farrell DJ and Mendes RE published in Antimicrob. Agents. Chemother. 2016; 60 (9): 5393-5399

Pharmacokinetics-pharmacodynamics of tazobactam in combination with piperacillin in an in vitro infection model.

Pharmacokinetics-pharmacodynamics of tazobactam in combination with piperacillin in an in vitro infection model. by Nicasio AM, VanScoy BD, Mendes RE, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN and Ambrose PG published in Antimicrob. Agents. Chemother. 2016; 60 (4): 2075-2080

Comparison of BD Max StaphSR and BD Max MRSAXT for screening of Staphylococcus aureus clinical isolates collected from hospitals in the United States.

Comparison of BD Max StaphSR and BD Max MRSAXT for screening of Staphylococcus aureus clinical isolates collected from hospitals in the United States. by Mendes RE, Watters AA, Rhomberg PR, Farrell DJ and Jones RN published in J. Clin. Microbiol. 2016; 54 (6): 1668-1669

Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): Evolving resistance mechanisms with stable susceptibility rates.

Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): Evolving resistance mechanisms with stable susceptibility rates. by Mendes RE, Hogan PA, Jones RN, Sader HS and Flamm RK published in J. Antimicrob. Chemother. 2016; 71 (7): 1860-1865

In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States.

In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States. by Mendes RE, Farrell DJ, Flamm RK, Talbot GH, Ivezic-Schoenfeld Z, Paukner S and Sader HS published in Antimicrob. Agents. Chemother. 2016; 60 (7): 4407-4411

β-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates.

β-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates. by Mendes RE, Castanheira M, Gasink L, Stone GG, Nichols WW, Flamm RK and Jones RN published in Antimicrob. Agents. Chemother. 2016; 60 (3): 1328-1335

Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency.

Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency. by Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS and Jones RN published in J. Antimicrob. Chemother. 2016; 71 (12): 3453-3458

Multicenter investigation of gepotidacin (GSK2140944) agar dilution quality control determinations for Neisseria gonorrhoeae ATCC 49226.

Multicenter investigation of gepotidacin (GSK2140944) agar dilution quality control determinations for Neisseria gonorrhoeae ATCC 49226. by Jones RN, Fedler KA, Scangarella-Oman NE, Ross JE and Flamm RK published in Antimicrob. Agents Chemother. 2016; 60 (7): 4404-4406

In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).

In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013). by Huband MD, Castanheira M, Farrell DJ, Flamm RK, Jones RN, Sader HS and Mendes RE published in Int. J. Antimicrob. Agents. 2016; 47 (6): 495-499

In vitro activity of delafloxacin tested against isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

In vitro activity of delafloxacin tested against isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. by Flamm RK, Rhomberg PR, Huband MD and Farrell DJ published in Antimicrob. Agents Chemother. 2016; 60 (10): 6381-6385

In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents.

In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents. by Flamm RK, Rhomberg PR, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2016; 86 (1): 66-69

Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013).

Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013). by Flamm RK, Castanheira M, Streit JM and Jones RN published in Diagn. Microbiol. Infect. Dis. 2016; 85 (3): 352-355

International evaluation of MIC distributions and epidemiological cutoff value (ECV) definitions for fusarium species identified by molecular methods for the CLSI broth microdilution method.

International evaluation of MIC distributions and epidemiological cutoff value (ECV) definitions for fusarium species identified by molecular methods for the CLSI broth microdilution method. by Espinel-Ingroff A, Colombo AL, Cordoba S, Dufresne PJ, Fuller J, Ghannoum M, Gonzalez GM, Guarro J, Kidd SE, Meis JF, Melhem TM, Pelaez T, Pfaller MA, Szeszs MW, Takahaschi JP, Tortorano AM, Wiederhold NP and Turnidge J published in Antimicrob. Agents. Chemother. 2016; 60 (2): 1079-1084

Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014).

Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014). by Duncan LR, Smart JI, Flamm RK, Sader HS, Jones RN and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2016; 86 (3): 300-302

Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the USA (2013-2014).

Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the USA (2013-2014). by Duncan LR, Sader HS, Flamm RK, Jones RN and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2016; 86 (3): 303-306

Effect of the β-Lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae.

Effect of the β-Lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. by Castanheira M, Rhomberg PR, Flamm RK and Jones RN published in Antimicrob. Agents. Chemother. 2016; 60 (9): 5454-5458

Changes in the frequencies of β-lactamase genes among Enterobacteriaceae isolates in U.S. Hospitals, 2012 to 2014: Activity of ceftazidime-avibactam tested against β-lactamase-producing isolates.

Changes in the frequencies of β-lactamase genes among Enterobacteriaceae isolates in U.S. Hospitals, 2012 to 2014: Activity of ceftazidime-avibactam tested against β-lactamase-producing isolates. by Castanheira M, Mendes RE, Jones RN and Sader HS published in Antimicrob. Agents. Chemother. 2016; 60 (8): 4770-4777

Detection of mcr-1 among Escherichia coli clinical isolates collected worldwide as part of the SENTRY Antimicrobial Surveillance Program during 2014-2015.

Detection of mcr-1 among Escherichia coli clinical isolates collected worldwide as part of the SENTRY Antimicrobial Surveillance Program during 2014-2015. by Castanheira M, Griffin MA, Deshpande LM, Mendes RE, Jones RN and Flamm RK published in Antimicrob. Agents. Chemother. 2016; 60 (9): 5623-5624

High rates of nonsusceptibility to ceftazidime-avibactam and identification of New Delhi metallo-β-lactamase production in Enterobacteriaceae bloodstream infections at a major cancer center.

High rates of nonsusceptibility to ceftazidime-avibactam and identification of New Delhi metallo-β-lactamase production in Enterobacteriaceae bloodstream infections at a major cancer center. by Aitken SL, Tarrand JJ, Deshpande LM, Tverdek FP, Jones AL, Shelburne SA, Prince RA, Bhatti MM, Rolston KV, Jones RN, Castanheira M and Chemaly RF published in Clin. Infect. Dis. 2016; 63 (7): 954-958

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) P. aeruginosa Isolates from Hospitalized Patients with Bloodstream Infections and Pneumonia in European Medical Centres

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) P. aeruginosa Isolates from Hospitalized Patients with Bloodstream Infections and Pneumonia in European Medical Centres. Lead author: D Shortridge, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1246

Telavancin Activity against a Global Collection of Staphylococcus aureus Clinical Isolates (2013-2015)

Telavancin Activity against a Global Collection of Staphylococcus aureus Clinical Isolates (2013-2015). Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1356

β-lactamase Characterization of Baseline Gram-Negative Pathogens from a Phase 3 Trial of Ceftazidime-Avibactam (CAZ-AVI) for the Treatment of Nosocomial Pneumonia

β-lactamase Characterization of Baseline Gram-Negative Pathogens from a Phase 3 Trial of Ceftazidime-Avibactam (CAZ-AVI) for the Treatment of Nosocomial Pneumonia. Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P0408

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) Gram-Negative Organisms Collected from European Medical Centres

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) Gram-Negative Organisms Collected from European Medical Centres. Lead author: D Shortridge, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1271

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) Gram-Negative Organisms Collected from Latin America Medical Centres

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) Gram-Negative Organisms Collected from Latin America Medical Centres. Lead author: LR Duncan, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1272

Dalbavancin Tested against Staphylococcus aureus Isolates with Decreased Susceptibility to Glycopeptides and/or Lipopeptides from European Hospitals (2012-2016)

Dalbavancin Tested against Staphylococcus aureus Isolates with Decreased Susceptibility to Glycopeptides and/or Lipopeptides from European Hospitals (2012-2016). Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna Austria
# P0138

Activity of Tedizolid against Methicillin-Susceptible and -Resistant Staphylococcus aureus Pathogens Isolated from Patients in European Centres and Surrounding Regions

Activity of Tedizolid against Methicillin-Susceptible and -Resistant Staphylococcus aureus Pathogens Isolated from Patients in European Centres and Surrounding Regions. Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1344

Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Infections in Europe and Surrounding Areas (2014-2015)

Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Infections in Europe and Surrounding Areas (2014-2015). Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1502

Plazomicin Activity against European Enterobacteriaceae Isolates Carrying Aminoglycoside-Modifying Enzymes and 16S rRNA Methylases

Plazomicin Activity against European Enterobacteriaceae Isolates Carrying Aminoglycoside-Modifying Enzymes and 16S rRNA Methylases. Lead author: M Castanheira, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1281

In vitro Activity of Omadacycline and Comparators against Staphylococci, and Enterococci (including resistant organism subsets) from Patients in European medical Centres during 2016: Results from the SENTRY Antimicrobial Surveillance Program

In vitro Activity of Omadacycline and Comparators against Staphylococci, and Enterococci (including resistant organism subsets) from Patients in European medical Centres during 2016: Results from the SENTRY Antimicrobial Surveillance Program. Lead author: MD Huband, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1262

In vitro Activity of Omadacycline and Comparators against Gram-Negative Bacterial Isolates Collected from Patients in European Medical Centres (2016): Results from the SENTRY Antimicrobial Surveillance Program

In vitro Activity of Omadacycline and Comparators against Gram-Negative Bacterial Isolates Collected from Patients in European Medical Centres (2016): Results from the SENTRY Antimicrobial Surveillance Program. Lead author: MD Huband, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1253

Meropenem-Vaborbactam Activity against Enterobacteriaceae Isolates Collected during 2014-2015 from European Countries

Meropenem-Vaborbactam Activity against Enterobacteriaceae Isolates Collected during 2014-2015 from European Countries. Lead author: M Castanheira, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1286

Monitoring Echinocandin and Azole Susceptibility in a Global Collection of Invasive Fungal Isolates

Monitoring Echinocandin and Azole Susceptibility in a Global Collection of Invasive Fungal Isolates. Lead author: M Castanheira, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, 2017, Vienna, Austria
# P1748

In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary ABSSSI Isolates from Europe and Surrounding Areas (2014-2016): Results from the SENTRY Antimicrobial Surveillance Program

In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary ABSSSI Isolates from Europe and Surrounding Areas (2014-2016): Results from the SENTRY Antimicrobial Surveillance Program. Lead author: MD Huband, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1351